These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3392126)

  • 1. Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity.
    Gnudi S; Mongiorgi R; Moroni A; Bertocchi G
    J Clin Pharm Ther; 1988 Apr; 13(2):125-30. PubMed ID: 3392126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
    Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of mineral metabolism and bone turnover in osteoporotic females treated with phosphorus and salmon calcitonin.
    Cantatore FP; Carrozzo M; Magli DM; D'Amore M; Pipitone V
    Clin Rheumatol; 1987 Dec; 6(4):504-9. PubMed ID: 3502402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
    Civitelli R; Gonnelli S; Zacchei F; Bigazzi S; Vattimo A; Avioli LV; Gennari C
    J Clin Invest; 1988 Oct; 82(4):1268-74. PubMed ID: 3262626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX; Li H
    Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of Paget's disease of bone with salmon calcitonin.
    Sturtridge WC; Harrison JE; Wilson DR
    Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis.
    Overgaard K; Hansen MA; Dirksen KL; Christiansen C
    Calcif Tissue Int; 1992 Sep; 51(3):184-8. PubMed ID: 1422962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
    Rico H; Revilla M; Hernández ER; Villa LF; Alvarez de Buergo M
    Calcif Tissue Int; 1995 Mar; 56(3):181-5. PubMed ID: 7750020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
    Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
    Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
    Reginster JY; Denis D; Albert A; Deroisy R; Lecart MP; Fontaine MA; Lambelin P; Franchimont P
    Lancet; 1987 Dec; 2(8574):1481-3. PubMed ID: 2892047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.
    Mazzuoli GF; Passeri M; Gennari C; Minisola S; Antonelli R; Valtorta C; Palummeri E; Cervellin GF; Gonnelli S; Francini G
    Calcif Tissue Int; 1986 Jan; 38(1):3-8. PubMed ID: 3079649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin treatment of immobilization osteoporosis in rats.
    Tuukkanen J; Jalovaara P; Väänänen K
    Acta Physiol Scand; 1991 Jan; 141(1):119-24. PubMed ID: 2053438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to salmon calcitonin in chronic renal failure: relation to histological and biochemical indices of bone turnover.
    Cundy T; Heynen G; Gaspar S; Earnshaw M; Bartlett M; Paton S; Kanis JA
    Eur J Clin Invest; 1981 Jun; 11(3):177-84. PubMed ID: 6791936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium metabolism and 47calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis.
    Caniggia A; Gennari C; Bencini M; Cesari L; Borrello G
    Clin Sci; 1970 Apr; 38(4):397-407. PubMed ID: 5428804
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.
    Hodsman AB; Steer BM; Fraher LJ; Drost DJ
    Bone Miner; 1991 Jul; 14(1):67-83. PubMed ID: 1868270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.